To influence policy on critical issues like the Priority Review Voucher, biotech CEOs are forming consortiums and going to Washington as a unified group. This collaborative approach is more effective than individual company efforts because it demonstrates a widespread industry problem that needs a legislative solution.

The Trump administration's actions have eroded the long-standing trust that the federal government will provide stable, long-term research funding. This breakdown of the 'social contract' discourages scientists from pursuing ambitious, multi-decade longitudinal studies, which are crucial for major breakthroughs but are now perceived as too risky.

The market is currently ignoring the long-term impact of deep cuts to research funding at agencies like the NIH. While effects aren't immediate, this erosion of foundational academic science—the "proving ground" for new discoveries—poses a significant downstream risk to the entire biotech and pharma innovation pipeline.

The FDA is being pulled from its independent center by political pressure and leadership turnover. Biotech exec Jeremy Levin argues that while smaller players are speaking out, the 'titans' of the pharmaceutical industry are 'dead silent.' He suggests their silence allows the erosion to continue, threatening the predictability and integrity of the entire system.

Pfizer's CEO was named a "Best CEO" not for pipeline success but for effectively managing political pressure from the Trump administration. He made deals that appeased the White House on drug pricing without harming shareholder value, highlighting how a modern pharma CEO's job now heavily involves navigating the political landscape.

The current political and regulatory environment means running a biotech company is no longer just about science and capital. CEOs must now actively engage in policy discussions and lobby legislators to ensure the ecosystem remains favorable for innovation. Ignoring politics is no longer an option.

An unprecedentedly specific executive order on psychedelics signals that political influence can now directly shape FDA priorities. This suggests biopharma companies may now need a political strategy—alongside clinical and regulatory plans—to maximize their chances of success for certain high-profile drug classes.

The key risk facing biomedical innovation is not just policy chaos, but the normalization of political and ideological influences on science-based regulation. This includes CEOs negotiating prices with the president and FDA enforcing pricing policies, breaking long-standing norms that separated science from politics.

Individual biotech executives are reluctant to publicly challenge the FDA because their companies have drugs under active review. Forming a broad coalition with investors and patient advocates allows them to voice concerns collectively, providing a shield against potential regulatory blowback that any single company might face if it spoke out alone.